Daclatasvir Dihydrochlorid
Beschreiwung
Daclatasvir Dihydrochlorid (BMS-790052 Dihydrochlorid) ass eng mächteg a mëndlech aktivHCV NS5A Proteininhibitor matEC50s Gamme vun 9-146 pm firMultiple HCV Replikon Genotypen.Daclatasvir Dihydrochlorid ass och engorganesch Anion transportéierend Polypeptid 1B (OATP1B)anOATP1B3inhibitor matIC50s vun 1,5 µM respektiv 3,27 µM.
IC50& Zil
EC50: 50 pM (HCV Replicon Genotyp 1a), 9 pM (HCV Replicon Genotyp 1b), 71 pM (HCV Replicon Genotyp 2a), 146 pM (HCV Replicon Genotyp 3a), 12 pM (HCV Replicon Genotyp 33 pM) HCV Replicon Genotyp 5a)[1]
Kd: 8 nM (NS5A33-202) an 210 nM (NS5A26-202)[2]
IC50: 1,5 µM (OATP1B) an 3,27 µM (OATP1B3)[3]
In Vitro
Daclatasvir (BMS-790052) weist mächteg hemmungsaktiv Aktivitéit géint all getest Genotypen, mat EC50Wäerter vun 9 bis 146 Auer.Daclatasvir hemmt HCV Replikon Genotyp 1a, 1b, 2a, 3a, 4a a 5a mat EC50Wäerter vun 50 pM, 9 pM, 71 pM, 146 pM, 12 pM an 33 pM, respektiv.Daclatasvir ass e mächtege Inhibitor vum JFH-1 Genotyp 2a ustiechend Virus deen an der Zellkultur replizéiert (EC)50= 28 Uhr)[1].Daclatasvir (BMS-790052) bindt enk un NS5A33-202 an NS5A26-202 mat Kds vun 8 nM an 210 nM, respektiv[2].
Stockage
| Pudder | -20°C | 3 Joer |
| 4°C | 2 Joer | |
| Am Léisungsmëttel | -80°C | 6 Méint |
| -20°C | 1 Mount |
Klinesch Prozess
| NCT Zuel | Sponsor | Zoustand | Ufanks Datum | Phase |
| NCT03369327 | Teheran University of Medical Sciences|RojanPharma Pharmaceutical Company | Hepatitis C Virus Infektioun, Äntwert op Therapie vum Mënsch Immunodeficiency Virus | 1. Januar 2017 | Phase 3 |
| NCT03485846 | R-Pharm|Almedis | Chronesch Hepatitis C Genotyp 1b | 27. November 2017 | Phase 2 |
| NCT01016912 | Bristol-Myers Squibb | Hepatitis C Infektioun | Dezember 2009 | Phase 2 |
| NCT01629732 | Bristol-Myers Squibb | Hepatitis C Virus | Mäerz 2013 | Phase 2 |
| NCT01497834 | Bristol-Myers Squibb | Hepatitis C | Januar 2012 | Phase 3 |
| NCT01973049 | Bristol-Myers Squibb | Hepatitis C | Dezember 2013 | Phase 3 |
| NCT00663208 | Bristol-Myers Squibb | Chronesch Hepatitis C | Mee 2008 | Phase 2 |
| NCT02576314 | Humanity and Health Research Centre|Beijing 302 Hospital | Chronesch Hepatitis C Infektioun | Mee 2015 | Phase 3 |
| NCT02756936 | Genuine Research Center, Egypt|Zeta Pharma Pharmaceutical Industries | Gesond | Februar 2016 | Phase 1 |
| NCT02771405 | National Hepatology & Tropical Medicine Research Institute | Kairo Universitéit | Hepatitis C, Chronesch|Hepatocellulär Karzinom | Mäerz 2016 | Phase 3 |
| NCT03706898 | Viriom | HIV-1-Infektioun|Hepatesch Behënnerung | 1. Oktober 2018 | Phase 1 |
| NCT02319031 | Bristol-Myers Squibb | Hepatitis C | Februar 2015 | Phase 3 |
| NCT02124044 | National Institutes of Health Clinical Center (CC)|National Institute of Allergy and Infectious Diseases (NIAID)|Bristol-Myers Squibb | HIV-HCV | Februar 2014 | Phase 2 |
| NCT02551861 | Bristol-Myers Squibb | Hepatitis C | Dezember 2015 | Phase 2 |
| NCT00859053 | Bristol-Myers Squibb | Hepatesch Insuffizienz | März 2009 | Phase 1 |
| NCT01257204 | Bristol-Myers Squibb | Hepatitis C Virus | Dezember 2010 | Phase 2 |
| NCT03063879 | Teheran University of Medical Sciences|Ahvaz Jundishapur University of Medical Sciences|Shiraz University of Medical Sciences|Hamadan University of Medical Science | Hepatitis C, Chronesch|Chronesch Nieralfehler | Abrëll 1, 2017 | Phase 4 |
| NCT01017575 | Bristol-Myers Squibb | Hepatitis C Infektioun | Dezember 2009 | Phase 2 |
| NCT02865369 | Sang Gyune Kim|Seoul National University Boramae Hospital|Severance Hospital|Inha University Hospital|Korea University|Gachon University Gil Medical Center|Hanyang University Seoul Hospital|Ewha Womans University Mokdong Hospital|Bristol-Myers Squibb|Soonchunhyang University Hospital | Chronesch Hepatitis C | September 2016 |
|
| NCT04070235 | Nanjing Sanhome Pharmaceutical, Co., Ltd. | Hepatitis C, chronesch | 29. Mäerz 2019 | Phase 2|Phase 3 |
| NCT03487848 | Bristol-Myers Squibb | Hepatitis C | Chronesch Hepatitis | Mee 18, 2018 | Phase 2 |
| NCT00904059 | Bristol-Myers Squibb | Hepatitis C | Mee 2009 | Phase 1 |
| NCT02107365 | Franséisch Institut national fir Gesondheet a Medizinesch Fuerschung-Franséisch National Agentur fir Fuerschung iwwer AIDS a Viral Hepatitis (Inserm-ANRS)|Bristol-Myers Squibb | Hepatitis C Virus Genotyp 4 Infektioun | November 2013 | Phase 2 |
| NCT02397395 | Janssen R&D Irland | Nierenausfall|Endstadium Nier Krankheet | Mee 2015 | Phase 2 |
| NCT03169348 | Assiut Universitéit | Hepatitis C | 1. November 2017 | Net zoutreffend |
| NCT02323594 | Bristol-Myers Squibb | Hepatitis C Infektioun | Dezember 2014 | Phase 1 |
| NCT03537196 | Franséisch Institut national fir Gesondheet a Medizinesch Fuerschung - Franséisch National Agentur fir Fuerschung iwwer AIDS a Viral Hepatitis (Inserm-ANRS) | Hepatitis C|Medikamenter benotzt|Viral Hepatitis C | November 13, 2018 | Phase 4 |
| NCT02103569 | Bristol-Myers Squibb | Hepatitis C | Abrëll 2014 | Phase 1 |
| NCT02772744 | Zagazig Universitéit|Kairo Universitéit | Hepatitis C | 1. November 2017 |
|
| NCT01718158 | Bristol-Myers Squibb | Hepatitis C | Januar 2013 | Phase 3 |
| NCT02496078 | Bristol-Myers Squibb | Hepatitis C | August 2015 | Phase 3 |
| NCT01425970 | Bristol-Myers Squibb | Hepatitis C | Mee 2012 | Phase 2 |
| NCT01471574 | Bristol-Myers Squibb | Hepatitis C, Genotyp 1 | Dezember 2011 | Phase 3 |
| NCT01573351 | Bristol-Myers Squibb | Hepatitis C Virus | Mee 2012 | Phase 3 |
| NCT01938625 | Janssen R&D Irland | Hepatitis C, chronesch | 12. Dezember 2013 | Phase 2 |
| NCT01492426 | Bristol-Myers Squibb | Hepatitis C | Januar 2012 | Phase 3 |
| NCT03480932 | Johns Hopkins Bloomberg School of Public Health|National Institute on Drug Abuse (NIDA)|YR Gaitonde Center for AIDS Research and Education | Hepatitis C, chronesch | 2. Februar 2018 | Phase 2|Phase 3 |
| NCT03163849 | Assiut Universitéit | Chronesch Hepatitis c | September 1, 2019 | Phase 3 |
| NCT01581203 | Bristol-Myers Squibb | Hepatitis C Virus | Mee 2012 | Phase 3 |
| NCT01492504 | Bristol-Myers Squibb | Hepatitis C | 7. Februar 2012 |
|
| NCT03686722 | Mohamed Raslan|Ain Shams University|Drug Research Center, Kairo, Ägypten | Diabetis mellitus, Typ 2 | Hepatitis C | Medikamenter Interaktiounen | September 9, 2017 | Phase 1 |
| NCT02262728 | Janssen Research & Development, LLC | Hepatitis C, chronesch | 30. September 2014 | Phase 2 |
| NCT02349048 | Janssen Research & Development, LLC | Hepatitis C Virus | Januar 2015 | Phase 2 |
| NCT03882307 | Assiut Universitéit | Hepatitis C, chronesch | Mee 2020 | Fréier Phase 1 |
| NCT02758509 | Parc de Salut Mar | Chronesch Hepatitis C | Zirrhose | 1. Januar 2010 |
|
| NCT01795911 | Bristol-Myers Squibb | Hepatitis C | Mäerz 2013 | Phase 2 |
| NCT03549832 | Assiut Universitéit|Sohag Universitéit|South Valley Universitéit | HCV Coinfection | Januar 1, 2018 | Net zoutreffend |
| NCT02161939 | Bristol-Myers Squibb | Chronesch Hepatitis C |
| |
| NCT01309932 | Bristol-Myers Squibb | Hepatitis C | Mäerz 2011 | Phase 2 |
| NCT01995266 | Bristol-Myers Squibb | Hepatitis C | 28. Februar 2014 | Phase 3 |
| NCT02640157 | Abb Vie | Chronesch Hepatitis C|Hepatitis C Virus|Genotyp 3 Hepatitis C Virus | Dezember 2015 | Phase 3 |
| NCT02032875 | Bristol-Myers Squibb | Hepatitis C | Mäerz 2014 | Phase 3 |
| NCT02624063 | Bundesuniversitéit vu São Paulo | Hepatitis C, chronesch | Dezember 2015 | Phase 4 |
| NCT00546715 | Bristol-Myers Squibb | Chronesch Hepatitis C | November 2007 | Phase 1|Phase 2 |
| NCT01718145 | Bristol-Myers Squibb | Hepatitis C Virus Infektioun | November 2012 | Phase 3 |
| NCT01616524 | Bristol-Myers Squibb | Hepatitis C Virus (HCV) | Juli 2012 | Phase 3 |
| NCT02032901 | Bristol-Myers Squibb | Hepatitis C | Januar 2014 | Phase 3 |
| NCT03540212 | Ain Shams Universitéit | Chronesch HCV Infektioun | Dezember 10, 2017 | Phase 2|Phase 3 |
| NCT02097966 | Bristol-Myers Squibb | Chronesch Hepatitis C |
| |
| NCT02596880 | Teheran University of Medical Sciences | Hepatitis C | Zirrhose | September 2015 | Phase 3 |
| NCT04019717 | D'Geschicht vun Atea Pharmaceuticals, Inc. | Hepatitis C|Hepatitis C, Chronesch|Chronesch Hepatitis C|Hepatitis C Virusinfektioun|HCV Infektioun | Juni 20, 2019 | Phase 2 |
| NCT02992457 | Tanta Universitéit | Hepatitis C | Januar 2015 | Phase 4 |
| NCT03547895 | Zagazig Universitéit | Dekompenséiert Zirrhosis | 1. Juni 2015 | Net zoutreffend |
| NCT03004625 | Kaohsiung Medical University Chung-Ho Memorial Hospital|Chang Gung Memorial Hospital|National Taiwan University Hospital|Taipei Veterans General Hospital, Taiwan|China Medical University Hospital|National Cheng-Kung University Hospital | Hepatitis C | November 2016 | Phase 3 |
| NCT01051414 | Bristol-Myers Squibb | Hepatitis C Infektioun | Abrëll 2010 | Phase 2 |
| NCT02309450 | Franséisch Institut national fir Gesondheet a Medizinesch Fuerschung-Franséisch National Agentur fir Fuerschung iwwer AIDS a Viral Hepatitis (Inserm-ANRS)|Bristol-Myers Squibb | Hepatitis C Virus Genotyp 4 Infektioun | Dezember 2014 | Phase 2 |
| NCT01628692 | Bristol-Myers Squibb|Janssen Research & Development, LLC | Hepatitis C Virus | Juli 2012 | Phase 2 |
| NCT03186313 | Ägyptesche Liewer Spidol|Wadi El Nil Spidol | Hepatitis C | September 2016 | Phase 3 |
| NCT03063723 | Drëtt verbonne Spidol, Sun Yat-Sen Universitéit | Chronesch Hepatitis C (Stéierungen) | 1. Januar 2016 |
|
| NCT00983957 | Bristol-Myers Squibb | Chronesch Hepatitis C | Oktober 2009 | Phase 1 |
| NCT01725542 | Franséisch Institut national fir Gesondheet a Medizinesch Fuerschung-Franséisch National Agentur fir Fuerschung iwwer AIDS a Viral Hepatitis (Inserm-ANRS)|Bristol-Myers Squibb | HCV-HIV Co-Infektioun | Dezember 2012 | Phase 2 |
| NCT02282709 | Fondatioun fir Liewer Fuerschung | Chronesch Hepatitis C | Februar 2014 | Phase 3 |
| NCT02032888 | Bristol-Myers Squibb | Hepatitis C | Februar 2014 | Phase 3 |
| NCT03247296 | MTI Universitéit | Hepatitis C | 28. Februar 2017 |
|
| NCT01389323 | Bristol-Myers Squibb | Hepatitis C | September 2011 | Phase 3 |
| NCT02556086 | Bristol-Myers Squibb | Hepatitis C | Dezember 2015 | Phase 2 |
| NCT01741545 | Bristol-Myers Squibb | Hepatitis C Virus | 31. Mäerz 2013 | Phase 3 |
| NCT01866930 | Bristol-Myers Squibb | Chronesch Hepatitis C Infektioun | 11. Juli 2013 | Phase 3 |
| NCT02268864 | Janssen-Cilag International NV | Hepatitis C, chronesch | Januar 2015 | Phase 2 |
| NCT01797848 | Bristol-Myers Squibb | Hepatitis C | Juni 2014 | Phase 3 |
| NCT03166280 | Eman Sayed Hassan Abd Allah|Assiut Universitéit | Hepatitis C | Juni 2017 |
|
| NCT02159352 | Bristol-Myers Squibb | Hepatitis C | Juni 2014 | Phase 1 |
| NCT01125189 | Bristol-Myers Squibb | Hepatitis C Virus | Juli 2010 | Phase 2 |
| NCT03748745 | Nanjing Sanhome Pharmaceutical, Co., Ltd. | Drogen Interaktiounen | November 19, 2018 | Phase 1 |
| NCT01012895 | Bristol-Myers Squibb | Chronesch Hepatitis C | Dezember 2009 | Phase 2 |
| NCT02565888 | Radboud Universitéit | Hepatitis C|HIV | November 2015 | Phase 1 |
| NCT02555943 | Humanity and Health Research Center|Beijing 302 Hospital|Nanfang Hospital of Southern Medical University | Chronesch Hepatitis C Infektioun|HBV Coinfection|Hepatitis B Reaktivéierung | Februar 2015 | Phase 2|Phase 3 |
| NCT02304159 | Tarek I. Hassanein, MD, FACP, FAG, AGAF|Southern California Research Center | Hepatitis C | Zirrhose | Januar 2015 | Phase 4 |
| NCT02580474 | Myeong Jun Song|Bristol-Myers Squibb|Soonchunhyang University Hospital|Dankook University|Chungnam National University Hospital|Konyang University Hospital|Eulji University Hospital|Saint Vincent's Hospital, Korea|Konkuk University Hospital|Cheongju St. Mary's Hospital, Cheongju , Korea|Severance Hospital|Korea University Guro Hospital|Eulji General Hospital|The Catholic University of Korea | Hepatitis C | Februar 2016 | Phase 4 |
| NCT02104843 | Bristol-Myers Squibb | Hepatitis C | Abrëll 2014 | Phase 1 |
| NCT01428063 | Bristol-Myers Squibb | Hepatitis C Virus Infektioun | September 2011 | Phase 2 |
| NCT02123654 | Bristol-Myers Squibb | Hepatitis C Virus Infektioun | Abrëll 2014 | Phase 3 |
| NCT02565862 | Radboud Universitéit | Hepatitis C | Diabetis Mellitus | Insulinresistenz | Januar 2016 | Phase 1 |
| NCT04211844 | Ain Shams Universitéit | Chronesch Hepatitis C | 1. Oktober 2019 |
|
| NCT00874770 | Bristol-Myers Squibb | Hepatitis C Infektioun | Juni 2009 | Phase 2 |
| NCT03883698 | Sanjay Gandhi Postgraduate Institut fir Medizinesch Wëssenschaften | Nierenausfall, Chronesch|Hepatitis C | Mäerz 15, 2019 | Phase 3 |
| NCT01448044 | Bristol-Myers Squibb | Hepatitis C | Dezember 2011 | Phase 3 |
| NCT01359644 | Bristol-Myers Squibb|Pharmasset | Chronesch Hepatitis C | Juni 2011 | Phase 2 |
| NCT01842451 | D'Kapitaliséierung vu Vertex Pharmaceuticals Incorporated ass haut | Chronesch Hepatitis C|CHC|HCV|Hepatitis C | Juni 2013 | Phase 2 |
| NCT02762448 | Tainan Municipal Spidol | Hepatitis c | Juli 2016 |
|
| NCT02473211 | Humanity and Health Research Centre|Beijing 302 Hospital | Chronesch Hepatitis C Infektioun | Januar 2015 | Phase 2|Phase 3 |
| NCT01455090 | Bristol-Myers Squibb | Chronesch Hepatitis C | 30. November 2011 | Phase 2 |
| NCT03490097 | Ain Shams Universitéit | Chronesch Hepatitis c | Metabolescht Syndrom | Dezember 1, 2017 | Phase 2|Phase 3 |
| NCT01170962 | Bristol-Myers Squibb | Hepatitis C Virus | August 2010 | Phase 2 |
| NCT02333292 | Valme University Hospital|Spidol del SAS de Jerez|Spidol General Universitario Elche|Spidol La Línea de la Concepción|Complexo Hospitalario Universitario de A Coruña|Spidol de Figueres|Spidol Universitario Puerto Real|Spidol Universitario Virgen de la Victoria|Spidol Universitario de Cannes | Spidol General Universitario de Alicante|Spidol Universitario Araba|Spidol Royo Vilanova|Spidol Universitario de Burgos|Complejo Hospitalario Universitario de Huelva|Spidol Universitario Reina Sofia de Cordoba|Spidol Universitario Virgen Macarena|Complexo Hospitalario Universitario de Vigo|Clinica de Navversidad Universidad Universidad Navarra|Spidol Clinico Universitario San Cecilio|Spidol Universitario La Fe|Spidol General Universitario de Valencia|Spidol Universitario Infanta Leonor|Spidol Universitario de Gran Canaria|Spidol General Universitario Santa Lucía|Centro Penitenciario Alicante 1|Spidol Haya Universitario de Carlario Virgen an Luz|Spidol General Universitario de Castellón|Spidol Parc Taulí, Sabadell | Chronesch Hepatitis C Infektioun | Dezember 2014 |
|
| NCT03200184 | Teheran University of Medical Sciences | Hepatitis C | September 1, 2016 | Phase 4 |
| NCT03188276 | Drëtt verbonne Spidol, Sun Yat-Sen Universitéit | Chronesch Hepatitis C | 1. Februar 2016 | Fréier Phase 1 |
| NCT01830205 | Bristol-Myers Squibb | Hepatitis C | September 2012 | Phase 1 |
Propositioun18Qualitéitskonsistenz Evaluatiounsprojeten déi guttgeheescht hunn4,an an6Projete sinn ënner Genehmegung.
Fortgeschratt international Qualitéitsmanagement System huet zolidd Fëllement fir Verkaf geluecht.
Qualitéitsiwwerwaachung leeft duerch de ganze Liewenszyklus vum Produkt fir d'Qualitéit an den therapeuteschen Effekt ze garantéieren.
Professional Regulatory Affairs Team ënnerstëtzt d'Qualitéitsfuerderunge wärend der Uwendung an der Aschreiwung.
Korea Countec Fläsche Verpackungslinn
Taiwan CVC Fläsche Verpackungslinn
Italien CAM Board Packaging Line
Däitsch Fette Compacting Machine
Japan Viswill Tablet Detektor
DCS Kontrollraum
International Zesummenaarbecht
Domestic Kooperatioun
Schreift äre Message hei a schéckt en un eis
